Cargando…

The Related Metabolic Diseases and Treatments of Obesity

Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ming, Liu, Shuai, Zhang, Chunye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498506/
https://www.ncbi.nlm.nih.gov/pubmed/36141228
http://dx.doi.org/10.3390/healthcare10091616
_version_ 1784794776050073600
author Yang, Ming
Liu, Shuai
Zhang, Chunye
author_facet Yang, Ming
Liu, Shuai
Zhang, Chunye
author_sort Yang, Ming
collection PubMed
description Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.
format Online
Article
Text
id pubmed-9498506
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94985062022-09-23 The Related Metabolic Diseases and Treatments of Obesity Yang, Ming Liu, Shuai Zhang, Chunye Healthcare (Basel) Review Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities. MDPI 2022-08-25 /pmc/articles/PMC9498506/ /pubmed/36141228 http://dx.doi.org/10.3390/healthcare10091616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yang, Ming
Liu, Shuai
Zhang, Chunye
The Related Metabolic Diseases and Treatments of Obesity
title The Related Metabolic Diseases and Treatments of Obesity
title_full The Related Metabolic Diseases and Treatments of Obesity
title_fullStr The Related Metabolic Diseases and Treatments of Obesity
title_full_unstemmed The Related Metabolic Diseases and Treatments of Obesity
title_short The Related Metabolic Diseases and Treatments of Obesity
title_sort related metabolic diseases and treatments of obesity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498506/
https://www.ncbi.nlm.nih.gov/pubmed/36141228
http://dx.doi.org/10.3390/healthcare10091616
work_keys_str_mv AT yangming therelatedmetabolicdiseasesandtreatmentsofobesity
AT liushuai therelatedmetabolicdiseasesandtreatmentsofobesity
AT zhangchunye therelatedmetabolicdiseasesandtreatmentsofobesity
AT yangming relatedmetabolicdiseasesandtreatmentsofobesity
AT liushuai relatedmetabolicdiseasesandtreatmentsofobesity
AT zhangchunye relatedmetabolicdiseasesandtreatmentsofobesity